查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1961129

皰疹樣皮膚炎治療市場 - 全球行業規模、佔有率、趨勢、機會、預測：按治療方法、病毒、最終用戶、地區和競爭對手分類，2021-2031 年

Herpangina Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By Virus, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球皰疹性咽峽炎治療市場預計將從 2025 年的 19.4 億美元成長到 2031 年的 29.4 億美元，複合年成長率為 7.17%。

該市場涵蓋藥物和輔助護理領域，尤其專注於治療兒童常見病毒感染疾病，這些感染通常表現為發燒和口腔潰瘍疼痛。主要成長要素包括腸病毒在托兒機構等人員密集環境中的傳播，以及全球兒童人口不斷成長，需要定期就醫。此外，意識提升，以及對即時緩解症狀的需求日益成長，推動了鎮痛藥和退燒藥作為第一線標準治療藥物的持續使用。

市場概覽
預測期 2027-2031
市場規模：2025年 19.4億美元
市場規模：2031年 29.4億美元
複合年成長率：2026-2031年 7.17%
成長最快的細分市場 柯薩奇A病毒
最大的市場 北美洲

另一方面，嚴重限制市場擴張的一個主要障礙是，疾病的自癒傾向削弱了製藥公司開發昂貴的標靶抗病毒療法的商業性動力。因此，儘管病例數量龐大，但製藥業嚴重依賴低利潤的學名藥，限制了總收入的潛力。台灣疾病管制署的報告顯示，在2024年疫情高峰期，因腸病毒感染疾病而就診的門診和急診人數每週將超過22,000人次，這凸顯了該疾病帶來的巨大負擔。

市場促進因素

全球兒童皰疹性咽峽炎的發病率上升是市場擴張的主要促進因素，確保了緩解症狀藥物的持續使用。在後疫情時代，腸病毒感染率不斷上升，醫護人員發現需要治療發燒和口咽潰瘍疼痛的兒童患者數量顯著增加。這種流行病學上的激增直接導致鎮痛藥、抗發炎藥物和局部麻醉劑的銷售成長，這些藥物在缺乏特異性抗病毒藥物的情況下被用作主要治療方法。例如，泰國國家經濟和社會發展委員會在其2025年9月發布的《2025年第二季經濟報告》中指出，手足口病（這些腸病毒的主要臨床表現）病例在該季度同比成長了65.7%，迫使生產商維持高產量。

此外，政府加強感染疾病防治措施，透過嚴格的監測系統和快速核准預防措施，刺激了市場活動。衛生部門正在建立更完善的監測通訊協定，並支持疫苗研發，以減輕EV71等嚴重病毒株的影響。這將有助於提高處方療法的有效性，並促進早期醫療干預。例如，越南衛生署在2025年2月發布的關於手足口病的聯合聲明中強調，鑑於前一年越南記錄了超過7.6萬例病例，核准該國首支疫苗至關重要。同樣，韓國疾病管理廳於2025年7月發布的2024年度感染疾病報告顯示，感染疾病病例總數增加了54.5%，凸顯了製定強力的疾病防治策略的迫切性。

市場挑戰

皰疹性咽峽炎的自癒特性對全球治療市場的經濟擴張構成重大障礙。由於這種病毒感染疾病通常在一週內自行消退，且無持續性併發症，因此臨床上並不迫切需要使用強效且昂貴的抗病毒療法。這種短暫的病程顯著降低了開發針對特異性疾病藥物的商業性可行性，導致製藥公司認為此類小眾產品的投資報酬率不足。因此，市場嚴重依賴利潤率低、市面上已有的鎮痛退燒藥物，儘管皰疹性咽峽炎頻繁爆發，但限制了產業相關人員的整體收入潛力。

這種情況造成了一種市場現象：病例數量眾多，但經濟價值卻極低。疾病的廣泛流行保證了對症治療的穩定需求，但卻並未促使人們採用昂貴的治療方法。例如，日本國立感染疾病研究所的一份報告就凸顯了這種差距：在2025年夏季疫情期間，日本每週皰疹性咽峽炎病例數峰值約為每個監測點4例。這些數據證實，由於疾病的短暫性，龐大的患者群體無法為製藥業帶來高利潤。

市場趨勢

快速分子診斷技術的整合正在革新皰疹性咽峽炎的臨床診療方法，實現病原體的精準鑑定。醫療機構正逐漸拋棄僅憑症狀診斷的傳統方法，轉而採用先進的多重PCR檢測技術。此技術對於區分引起皰疹性咽峽炎的克沙奇病毒與其他症狀相似的危險腸病毒株至關重要。這項技術進步最佳化了患者分診流程，並減少了病毒感染疾病中不必要的抗生素使用。美國微生物學會在2025年6月發布的報告《強化腸病毒基因組監測》中強調了精準監測的必要性。報告指出，詳細的分子篩檢在72.6%的腸病毒陽性檢體中檢出了EV-D68，凸顯了先進診斷技術在精準疾病追蹤中的關鍵作用。

同時，為了解決目前缺乏標靶治療方法的問題，一些研究重點正轉向廣譜抗腸病毒藥物。鑑於單純對症治療的局限性，製藥公司正積極研發新的治療類別，包括衣殼抑制劑和蛋白酶抑制劑，以對抗多種腸病毒血清型。這項策略轉變正推動市場從低成本鎮痛藥物轉向高價值的緩解疾病藥物，尤其是在預防高風險兒童族群出現嚴重併發症。 GeneOnline在2025年12月發表的報導《腸病毒將在六年內首次達到高峰》中預測，到2030年，非脊髓灰質炎病毒治療藥物市場規模將超過100億美元，這主要得益於對有效治療方法的迫切需求，也印證了這一方向的巨大經濟潛力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：皰疹性咽峽炎治療的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 治療方法（局部麻醉劑、Ibuprofen或乙醯胺酚、其他治療方法）
    • 依病毒類型（克沙奇病毒A、克沙奇病毒B、腸病毒71、人腸道孤病毒）
    • 依最終使用者（醫院、居家醫療、專科診所等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美皰疹性咽峽炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲皰疹性咽峽炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區皰疹性咽峽炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲皰疹病毒感染治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲皰疹病毒感染症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球皰疹性咽峽炎治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Gilead Sciences Inc
  • Johnson and Johnsons
  • Merck & Co. Inc
  • Pfizer Inc.
  • AbbVie Inc.
  • Vertex Pharmaceuticals Incorporated
  • Sanofi SA
  • Novartis AG
  • Mitsubishi Tanabe Pharma Corporation
  • F. Hoffmann-La Roche Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18977

The Global Herpangina Treatment Market is projected to expand from USD 1.94 Billion in 2025 to USD 2.94 Billion by 2031, registering a CAGR of 7.17%. This market encompasses pharmaceutical and supportive care sectors dedicated to managing a common viral infection in children, which is distinguished by fever and painful mouth ulcers. Key growth drivers include the rising transmission of enteroviruses in crowded childcare environments and a growing global pediatric population that requires regular medical attention. Additionally, heightened parental awareness regarding viral hygiene, coupled with the need for immediate symptom alleviation, supports the consistent use of analgesics and antipyretics as the primary standard of care.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.94 Billion
Market Size 2031USD 2.94 Billion
CAGR 2026-20317.17%
Fastest Growing SegmentCoxsackie Virus A
Largest MarketNorth America

Conversely, a major hurdle limiting extensive market growth is the self-limiting nature of the illness, which diminishes the commercial motivation for pharmaceutical firms to engineer expensive, targeted antiviral treatments. Consequently, the industry relies heavily on low-margin generic drugs, which constrains total revenue potential despite the large volume of cases. To illustrate the significant burden of the disease, data from the Taiwan Centers for Disease Control indicates that in 2024, weekly outpatient and emergency visits for enterovirus infections reached a peak of over 22,000 cases during the height of the epidemic season.

Market Driver

The increasing global prevalence of pediatric herpangina serves as a major catalyst for market expansion, ensuring the continuous use of medications for symptomatic relief. As enteroviral transmission rates climb in the post-pandemic landscape, healthcare professionals are observing a marked increase in young patients needing clinical care for fever and painful oropharyngeal ulcers. This epidemiological surge leads directly to greater sales of analgesics, anti-inflammatory agents, and topical anesthetics, which function as the primary treatment methods lacking specific antivirals. Demonstrating this trend, the National Economic and Social Development Council of Thailand reported in its 'Second Quarter 2025 Economic Report' in September 2025 that cases of hand, foot, and mouth disease-the main clinical manifestation of these enteroviruses-rose by 65.7% year-on-year during that quarter, compelling manufacturers to sustain high production levels.

Furthermore, government efforts to control infectious diseases boost market activity through strict surveillance and the accelerated approval of preventive measures. Health authorities are enacting stronger monitoring protocols and backing the creation of vaccines to reduce the impact of severe strains like EV71, which validates prescribed therapies and promotes early medical intervention. For example, the Vietnam Ministry of Health, in a February 2025 'Joint Statement on Hand-Foot-Mouth Disease', emphasized the critical need to approve the nation's first domestic vaccine following more than 76,000 recorded cases the prior year. Similarly, the Korea Disease Control and Prevention Agency's '2024 Annual Report on Notified Infectious Diseases', released in July 2025, showed a 54.5% rise in total infectious cases, highlighting the urgent requirement for robust disease management strategies.

Market Challenge

The self-limiting characteristic of herpangina represents a significant barrier to the financial expansion of the global treatment market. Since this viral infection usually clears up on its own within a week without leaving lasting effects, there is little clinical urgency to prescribe potent, expensive antiviral therapies. This brief duration markedly reduces the commercial feasibility of creating disease-specific medications, as pharmaceutical manufacturers view the return on investment for such niche products as inadequate. As a result, the market depends heavily on low-margin over-the-counter analgesics and antipyretics, limiting the total revenue potential for industry players despite frequent outbreaks.

This dynamic fosters a market landscape defined by high case numbers but disproportionately low financial value. While the widespread nature of the ailment guarantees consistent demand for supportive care, it does not lead to the uptake of premium therapeutic options. Highlighting this gap, the National Institute of Infectious Diseases reported that in 2025, weekly herpangina cases in Japan peaked at roughly 4.0 per sentinel site during the summer epidemic season. This data underscores the existence of a large patient population that, due to the temporary nature of the condition, generates only minimal high-value revenue for the pharmaceutical industry.

Market Trends

The integration of Rapid Molecular Diagnostic Technologies is revolutionizing the clinical approach to herpangina by facilitating exact pathogen identification. Medical providers are progressively moving away from reliance on symptoms alone to employing advanced multiplex PCR assays, which are essential for differentiating herpangina-causing Coxsackieviruses from other dangerous enteroviral strains with similar symptoms. This technological advancement improves patient triage and curtails the unnecessary use of antibiotics for viral infections. Emphasizing the need for such precise surveillance, the American Society for Microbiology noted in its June 2025 report, 'Enhanced genomic surveillance of enteroviruses', that detailed molecular screening identified EV-D68 in 72.6% of enterovirus-positive samples, highlighting the vital function of advanced diagnostics in accurate disease tracking.

Simultaneously, a specific research emphasis on Broad-Spectrum Anti-Enteroviral Agents is developing to tackle the absence of targeted curative treatments. Acknowledging the constraints of purely symptomatic care, pharmaceutical developers are vigorously investigating new therapeutic categories, including capsid inhibitors and protease inhibitors, intended to combat a broad spectrum of enterovirus serotypes. This strategic shift steers the market away from low-cost analgesics toward high-value disease-modifying medications, specifically to avert severe complications in at-risk pediatric groups. Confirming the significant economic promise of this direction, GeneOnline projected in its December 2025 article, 'Enterovirus Hits 6-Year Peak', that the non-polio enterovirus therapeutics sector will surpass $10 billion by 2030, fueled by the pressing demand for effective treatments.

Key Market Players

  • Gilead Sciences Inc
  • Johnson and Johnsons
  • Merck & Co. Inc
  • Pfizer Inc.
  • AbbVie Inc.
  • Vertex Pharmaceuticals Incorporated
  • Sanofi S.A
  • Novartis AG
  • Mitsubishi Tanabe Pharma Corporation
  • F. Hoffmann-La Roche Ltd

Report Scope

In this report, the Global Herpangina Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Herpangina Treatment Market, By Treatment

  • Topical Anesthetics
  • Ibuprofen or Acetaminophen
  • Other Treatments

Herpangina Treatment Market, By Virus

  • Coxsackie Virus A
  • Coxsackie Virus B
  • Enterovirus 71
  • Echovirus

Herpangina Treatment Market, By End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Herpangina Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Herpangina Treatment Market.

Available Customizations:

Global Herpangina Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Herpangina Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Topical Anesthetics, Ibuprofen or Acetaminophen, Other Treatments)
    • 5.2.2. By Virus (Coxsackie Virus A, Coxsackie Virus B, Enterovirus 71, Echovirus)
    • 5.2.3. By End User (Hospitals, Homecare, Specialty Clinics, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Herpangina Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Virus
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Herpangina Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By Virus
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Herpangina Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By Virus
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Herpangina Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By Virus
        • 6.3.3.2.3. By End User

7. Europe Herpangina Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By Virus
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Herpangina Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By Virus
        • 7.3.1.2.3. By End User
    • 7.3.2. France Herpangina Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By Virus
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Herpangina Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By Virus
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Herpangina Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By Virus
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Herpangina Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By Virus
        • 7.3.5.2.3. By End User

8. Asia Pacific Herpangina Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Virus
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Herpangina Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By Virus
        • 8.3.1.2.3. By End User
    • 8.3.2. India Herpangina Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By Virus
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Herpangina Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By Virus
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Herpangina Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By Virus
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Herpangina Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By Virus
        • 8.3.5.2.3. By End User

9. Middle East & Africa Herpangina Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By Virus
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Herpangina Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By Virus
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Herpangina Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By Virus
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Herpangina Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By Virus
        • 9.3.3.2.3. By End User

10. South America Herpangina Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By Virus
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Herpangina Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By Virus
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Herpangina Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By Virus
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Herpangina Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By Virus
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Herpangina Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Gilead Sciences Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Johnson and Johnsons
  • 15.3. Merck & Co. Inc
  • 15.4. Pfizer Inc.
  • 15.5. AbbVie Inc.
  • 15.6. Vertex Pharmaceuticals Incorporated
  • 15.7. Sanofi S.A
  • 15.8. Novartis AG
  • 15.9. Mitsubishi Tanabe Pharma Corporation
  • 15.10. F. Hoffmann-La Roche Ltd

16. Strategic Recommendations

17. About Us & Disclaimer